Načítá se...
Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus
As a clinical setting in which local live biological therapy is already well established, non-muscle invasive bladder cancer (NMIBC) presents intriguing opportunities for oncolytic virotherapy. Coxsackievirus A21 (CVA21) is a novel intercellular adhesion molecule-1 (ICAM-1)-targeted immunotherapeuti...
Uloženo v:
| Vydáno v: | Mol Ther Oncolytics |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society of Gene & Cell Therapy
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6035483/ https://ncbi.nlm.nih.gov/pubmed/29989024 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omto.2018.02.001 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|